VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
US Market

VistaGen Therapeutics Stock Price & Analysis

574 Followers

VTGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.08 - $2.11
Previous Close$0.14
Volume2.98M
Average Volume (3M)5.86M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$35.29M
Total Debt (Recent Filing)$3.57M
Price to Earnings (P/E)-0.4
Beta0.17
Next EarningsFeb 13, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.31
Shares Outstanding206,836,345
R-Squared0.00667
Standard Deviation0.33
10 Day Avg. Volume3,462,081
30 Day Avg. Volume5,856,301
Price to Book (P/B)0.96
Price to Sales (P/S)-151.56
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside84.50% Upside
Rating ConsensusHold
Alpha0.02
Number of Analyst Covering2


Financials


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

VTGN FAQ

What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.08 and its highest was $2.11 in the past 12 months.
    What is VistaGen Therapeutics’s market cap?
    Currently, no data Available
    When is VistaGen Therapeutics’s upcoming earnings report date?
    VistaGen Therapeutics’s upcoming earnings report date is Feb 13, 2023 which is in 72 days.
      How were VistaGen Therapeutics’s earnings last quarter?
      VistaGen Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.067 by -$0.013.
        Is VistaGen Therapeutics overvalued?
        According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does VistaGen Therapeutics pay dividends?
          VistaGen Therapeutics does not currently pay dividends.
          What is VistaGen Therapeutics’s EPS estimate?
          VistaGen Therapeutics’s EPS estimate is -$0.05.
            How many shares outstanding does VistaGen Therapeutics have?
            VistaGen Therapeutics has 206,836,350 shares outstanding.
              What happened to VistaGen Therapeutics’s price movement after its last earnings report?
              VistaGen Therapeutics reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.067. Following the earnings report the stock price went up 23.077%.
                Which hedge fund is a major shareholder of VistaGen Therapeutics?
                Among the largest hedge funds holding VistaGen Therapeutics’s share is Sitrin Capital Management Llc. It holds VistaGen Therapeutics’s shares valued at N/A.

                  ---

                  VistaGen Therapeutics Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -92.35%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -116.96%
                  Trailing 12-Months
                  Asset Growth
                  -59.50%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  VistaGen Therapeutics

                  VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Comera Life Sciences Holdings
                  Molecular Templates
                  Regulus
                  Arca Biopharma
                  Pasithea Therapeutics Corp

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis